Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients
This study has been completed.
Sponsored by: Orphan Medical
Information provided by: Orphan Medical
ClinicalTrials.gov Identifier: NCT00086281
  Purpose

To study the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in patients with obstructive sleep apnea syndrome (OSAS).


Condition Intervention Phase
Obstructive Sleep Apnea Syndrome
Drug: Xyrem
Drug: Zolpidem + Xyrem Placebo
Drug: Xyrem + modafinil
Drug: Placebo
Phase IV

MedlinePlus related topics: Club Drugs Sleep Apnea
Drug Information available for: Modafinil Sodium oxybate Zolpidem
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title: Randomized, Placebo-Controlled Multicenter Trial of the Effects of Orally Administered Xyrem (Sodium Oxybate) and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

Further study details as provided by Orphan Medical:

Primary Outcome Measures:
  • The primary efficacy variable was the AHI, determined from the polysomnogram (PSG). The AHI was defined as the incidence (events per hour) of apnea and hypopnea events associated with sleep. [ Time Frame: One night of PSG during one night of treatment each per arm. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Duration and severity of oxygen desaturation. [ Time Frame: One night of PSG during one night of treatment each per arm. ] [ Designated as safety issue: Yes ]

Enrollment: 60
Study Start Date: November 2003
Study Completion Date: November 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Xyrem 9 grams given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later
Drug: Xyrem
Xyrem oral solution, 9 g per night in divided doses. 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later.
2: Active Comparator
Zolpidem 10 mg + placebo were given at bedtime and placebo given 2.5 to 4 hours later.
Drug: Zolpidem + Xyrem Placebo
Zolpidem 10 mg oral tablets + Xyrem placebo were given at bedtime.
3: Experimental
Xyrem 9 g + modafinil 200 mg (Xyrem 9 g was given in a divided dose: 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later; modafinil was given at 8 am on the morning of Xyrem treatment).
Drug: Xyrem + modafinil
Xyrem oral solution 9 g per night in divided doses. 4.5 g at bedtime and 4.5 g given 2.5 to 4 hours later. Modafinil oral tablets was given at 8 am of the morning of Xyrem treatment.
4: Placebo Comparator
Placebo was given at bedtime and again 2.5 to 4 hours later.
Drug: Placebo
Placebo oral solution was given at bedtime and 2.5 to 4 hours later.

Detailed Description:

This study will be conducted as a randomized, crossover study of the effect of Xyrem (9 g), Xyrem (9 g) plus modafinil 200 mg administered the morning prior to Xyrem, positive control (zolpidem 10 mg), and placebo on the frequency and outcome of events of sleep-disordered breathing in patients with obstructive sleep apnea syndrome (OSAS).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed and dated an informed consent prior to beginning protocol required procedures.
  • Willing and able to complete the entire trial as per the protocol including 6 nights in the sleep lab.
  • 18 years of age or older.
  • Have a history of obstructive sleep apnea syndrome (as per American Academy of Sleep Medicine [AASM] Task Force 1999).
  • Apnea-Hypopnea Index(AHI): 10 to 40 inclusive, lowest O2 saturation ≥75% (see AASM Task Force 1999 criteria)
  • Females may be included who are surgically sterile, two years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) and agree to continue use of this method for the duration of the trial.
  • In the opinion of the investigator have adequate support for the duration of the trial to include transportation to and from the trial site. In addition, if in the investigator's assessment it is clinically indicated, the patient is willing to not operate a car or heavy machinery for the duration of the trial or for as long as the investigator deems clinically indicated.

Exclusion Criteria:

  • Have taken sodium oxybate (GHB) in the last 30 days.
  • Have taken any investigational therapy within the 30-day period prior to the initial screening visit for this trial.
  • Are routinely taking any stimulant medications, sedative hypnotics, tranquilizers, antihistamines (except for non-sedating antihistamines), benzodiazepines or clonidine at the start of the study. Patients taking anticonvulsants are not eligible to participate even if they are willing to washout anticonvulsants for the trial.
  • Regularly consume alcohol and are unwilling or unable to totally abstain from alcohol use for the trial duration.
  • Are experiencing any major illness, including unstable cardiovascular, endocrine, neoplastic, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurological, pulmonary, and/or renal disease which would place the patient at risk during the trial or compromise the objectives outlined in the protocol.
  • Have psychiatric disorders, major affective or psychotic disorders, or other problems that, in the investigator's opinion, would preclude the patient's participation and completion of this trial or compromise reliable representation of subjective symptoms.
  • Have a current or recent (within one year) history of a substance use disorder including alcohol abuse as defined by the DSM-IV.
  • Have a serum creatinine greater than 2.0 mg/dL, abnormal liver function tests (SGOT [AST] or SGPT [ALT] more than twice the upper limit of normal), or elevated serum bilirubin (more than 1.5 times the upper limit of normal), or pre-trial ECG results demonstrating clinically significant arrhythmias, greater than a first degree AV block or a history of myocardial infarction within the last six months.
  • Have an occupation that requires variable shift work or routine night shift.
  • Have a clinically significant history of seizure disorder either past or present, a history of clinically significant head trauma (i.e., concussion resulting in clinically significant loss of consciousness) or past invasive intracranial surgery, and are taking anticonvulsant medications.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00086281

Locations
United States, Florida
Clinical Research Group of St. Petersburg
St. Petersburg, Florida, United States, 33707
Canada, Ontario
London Health Sciences Centre, Victoria Campus
London, Ontario, Canada, N6A 4G5
Sponsors and Collaborators
Orphan Medical
Investigators
Study Director: Yanping Zheng, MD Jazz Pharmaceuticals, Inc.
  More Information

Trial results  This link exits the ClinicalTrials.gov site

Publications:
Responsible Party: Jazz Pharmaceuticals, Inc. ( Senior Director Clinical Development )
Study ID Numbers: OMC-SXB-23
Study First Received: June 29, 2004
Last Updated: May 22, 2008
ClinicalTrials.gov Identifier: NCT00086281  
Health Authority: United States: Food and Drug Administration

Keywords provided by Orphan Medical:
Sleep-disordered breathing
Obstructive sleep apnea syndrome

Study placed in the following topic categories:
Zolpidem
Sleep Apnea Syndromes
Apnea
Sleep Apnea, Obstructive
Respiration Disorders
Sleep Disorders
Dyssomnias
Modafinil
Sleep Disorders, Intrinsic
Signs and Symptoms
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Sodium Oxybate

Additional relevant MeSH terms:
Anesthetics, Intravenous
Neurotransmitter Agents
Disease
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Central Nervous System Stimulants
Protective Agents
Neuroprotective Agents
Pharmacologic Actions
Adjuvants, Anesthesia
Pathologic Processes
Anesthetics, General
GABA Agonists
Syndrome
Therapeutic Uses
Hypnotics and Sedatives
GABA Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009